Please assess the completion status of the following clinical trial:

Trial Title: Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Cytologic of histologic proof of pancreatic ductal carcinoma~* No evidence of metastatic disease~* 18 years of age or older~* ECOG Performance Status of 0 or 1 - Lab values as outlined in the protocol~Exclusion Criteria:~* Tumors in the body or tail of the pancreas~* Hepatic or peritoneal metastases detected by imaging or laparoscopy prior to chemoradiation~* Serious concomitant systemic disorders incompatible with the study, such as significant cardiac or pulmonary morbidity, ongoing infection as manifested by fever~* Pregnant or lactating women~* Life expectancy of \< 3 months~* Serious, uncontrolled, concurrent infection (s)~* Prior chemotherapy or radiation for treatment of the patient's pancreatic tumor~* Clinically significant cardiac disease or myocardial infarction within the last 12 months~* Other serious uncontrolled medical condition that the investigator feels might compromise study participation~* Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome~* Known, existing uncontrolled coagulopathy~* Any prior fluoropyrimidine therapy~* Prior unanticipated severe reaction to fluoropyrimidine therapy, or known hypersensitivity to a 5-fluorouracil or known DPD deficiency~* Participation in any investigational drug study within 4 weeks preceding the start of the study~* History of uncontrolled seizures, central nervous system disorders or psychiatric disability~* Major surgery, excluding laparoscopy, within 4 weeks of the start of study treatment, without complete recovery~* Patients on cimetidine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): 10 Radiation Sessions over 2 weeks
- Group 2 (Type: EXPERIMENTAL): 5 Radiation sessions: 3 in week 1 and 2 in week 2
- Group 3 (Type: EXPERIMENTAL): 5 Radiation sessions: 4 in week 1 and 1 in week 2
- Group 4 (Type: EXPERIMENTAL): 5 Radiation Sessions in one week

Based on this trial design, predict the completion outcome and termination type (if applicable).